Focus Day

8:30 am Coffee & Registration

9:00 am

Targeting Solid Tumors

Tumor Microenvironment

9:00 CAR-T Cells & Solid Tumors: Few Sizes May Fit All
• Solid tumor biology is becoming predictable
• “One size” may not, but a few may fit all immune landscapes
• CAR-T cells can be programmed to react to the nuances of the tumor microenvironment

Franco Marincola, Chief Scientific Officer, Refuge Biotechnologies

9:30 Advancing CAR T Cells for Solid Tumors: Prostate Cancer & Beyond

• Developing PSCA-CAR T cells for bone metastatic prostate cancer
• Building preclinical models to evaluate tumor microenvironment
• Future combination strategies for effective immunotherapy

Saul Priceman, Assistant Research Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center

Gene Editing Technologies
TCR-T Cell Drug Development

10:00 am Morning Refreshments & Networking

11:30 am

Targeting Solid Tumors

Clinical Exploration

11:30 Key Considerations for Moving a Product into Development for Pivotal Registration
• Standard vs accelerated development
• Cross-functional alignment
• Trade-offs between speed and opportunity

Aiman Shalabi, Vice President R&D, GlaxoSmithKline

Promising Targeting Strategies

12:00 CAR Macrophages: Tailor-Made for Solid Tumor Immunotherapy

•Current challenges in solid tumor cell therapy
• Overview of the Carisma CAR Macrophage platform
• The promise of CAR Macrophages in solid tumors

Michael Klichinsky, Co-Founder & VP, Discovery Research, Carisma Therapeutics

Gene Editing Technologies
TCR-T Cell Drug Development

12:30 pm Lunch & Networking

2:00 pm

Targeting Solid Tumors

Tumor Microenvironment

14:00 Conduit CAR-T: A Decoupled Approach to Solid Tumor Targeting with a Modular Chimeric Antigen Receptor T Cells
• Molecular design strategies to overcome immune surveillance, heterogeneity and antigen escape in solid tumors
• Decoupled approach: Modular CAR-T and a tunable mono/multi-specificity for tumor targeting
• Flexible design ensures safety when adverse events are not-manageable.

Rajkumar Ganesan, Director of Antibody Engineering & Bispecifics, The Janssen Pharmaceutical Companies of Johnson & Johnson

14:30 Breaching the Wall: Driving Potential Efficacy in Solid Tumors with a Multi-Antigen Targeted Approach to Cell Therapy

• TCR approaches in synovial sarcoma have yielded interesting initial results, but have delivered only transient responses to date
• Pancreatic cancer is considered one of the most difficult solid tumor indications for immuno-oncology, particularly cell therapies
• Review how a non-genetically modified, multi-antigen specific approach using MAST T cells may overcome these challenges in some of the most difficult solid tumors like pancreatic cancer

Peter Hoang, Chief Exectuive Officer, Marker Therapeutics

Gene Editing Technologies
TCR-T Cell Drug Development

3:00 pm End of Focus Day